Agitation days showed higher median sample entropy (1.23 vs 1.06; p<0.001) and approximate entropy (1.24 vs 1.08; p<5 × 10−19). 5 key findings →
Participants: 114 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Default thresholds yielded 20–23% precision with 94– 100% recall—unacceptable for caregiver-facing alerts. 5 key findings →
Participants: 51 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer disease (AD) is a disorder of the nervous system that mostly impacts the brain cells and causes the slow destruction of the brain. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with peripheral artery disease (PAD), chronic limb-threatening ischemia (CLTI), and/or diabetic foot ulcer (DFU) are at increased risk for limb loss and death. 3 key findings →
Participants: 178,995 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Artificial-intelligence (AI) systems for Alzheimer’s disease (AD) increasingly use neuroimaging or spontaneous speech, but reported performance is difficult to interpret across studies because cohorts, endpoints, languages, preprocessing, and validation protocols differ. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Digital medication-management tools for Alzheimer's disease (AD) typically record only whether a dose was taken, leaving the temporal and behavioral structure of adherence largely unused as a predictive signal. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Natural language processing has been examined as a possible biomarker for cognitive decline and dementia, but it has also been associated with components of well-being and psychological distress. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
16/100
Among 9,386 propensity score-matched pairs of ND patients and controls, covariates were well balanced. 5 key findings →
Design: retrospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
Although advances have been made in dementia symptom management, early detection during stages when interventions are most effective remains a significant challenge. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Amyloid-β deposition begins in the earliest preclinical stages of Alzheimer's disease, long before cognitive decline is detectable by standard clinical assessments, which are often limited by ceiling effects and create a need for non-invasive, scalable markers. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Early detection of Alzheimer’s disease (AD) from spontaneous speech remains a clinically significant challenge. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The observed protective effect may be explained by vascular and neuroprotective mechanisms unique to PDE5 inhibitors. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
White matter hyperintensities (WMHs) are a hallmark of cerebral small vessel disease, commonly seen in cognitively normal older adults and patients with neurodegenerative disorders, and are thought to reflect varying degrees of tissue damage. 2 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
16/100
Frontotemporal dementia (FTD) caused by progranulin (GRN) mutations is associated with pronounced thalamic degeneration, yet the cellular basis of selective thalamic vulnerability remains poorly understood. 3 key findings →
Participants: 92 Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid plaques contain numerous proteins in addition to amyloid beta in Alzheimer’s disease (AD). 4 key findings →
Participants: 240 Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with Down syndrome (DS) develop a genetic form of Alzheimer’s disease (AD) due to an extra copy of chromosome 21, which contains the APP gene. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 10,489 participants with incident MCI, the mean age at the incident MCI wave was 70.6 years (SD = 11.53), and 56.6% were female. 5 key findings →
Design: cohort study Participants: 10,489 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 1,231 patients (87.2% women; mean age 46.0 ± 13.7 years; 71.5% chronic migraine), 1,175/1,231 (95.5%) endorsed cognitive symptoms, with a mean Mig-SCog total score of 8.2 ± 4.8. 5 key findings →
Design: cross-sectional Participants: 661 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Isolated rapid eye movement sleep behaviour disorder (iRBD) strongly predicts future Lewy body disease and identifies a more aggressive, non-motor phenotype in Parkinson’s disease (PD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Magnetic resonance imaging (MRI) of the brain routinely combines complementary contrasts—including T1-weighted (T1w), T2-weighted (T2w) and FLAIR sequences—to capture anatomy and pathology. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study aimed to address these limitations by examining whether multilingual experience is associated with longitudinal ageing trajectories across objective and subjective measures spanning cognitive, affective, linguistic, and non-linguistic domains. 5 key findings →
Design: cross-sectional Participants: 193 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The neurodegenerative processes underlying Alzheimer’s disease and related dementias (ADRD) begin years before clinical diagnosis, motivating scalable approaches for earlier identification. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Older adults with mild cognitive impairment (MCI) or dementia have elevated fall risk, but fall-related psychological outcomes represent distinct constructs that should not be pooled indiscriminately. 5 key findings →
Participants: 327 Evidence: high
Full summary, score breakdown and related studies → Original source
Fairness in clinical machine-learning (ML) remains a critical challenge, particularly in neurodegenerative disease where demographic factors may confound disease-related patterns. 1 key finding →
Participants: 757 Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings indicate that all methods captured AD disconnection patterns but exhibited variability in preserving connectivity profiles, which seemed non-random but rather systematically linked to clinical measures and predictive power for AD classification. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →